
Opinion|Videos|June 21, 2024
Tackling Key Concerns in Atopic Dermatitis + Biologic Use
Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, address the critical clinical challenges in treating atopic dermatitis (AD) patients and discuss current trends in biologics use for AD.
Advertisement
- As it relates to the current treatment landscape for atopic dermatitis, what are the most pressing clinical concerns in treating patients with this disease?
- What trends are you seeing related to the use of biologics and injectables in the management of AD, and what are the cost implications of these trends?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
4
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
5